The Tachi Ya­ma­da lega­cy tree con­tin­ues to grow with a new gene edit­ing biotech from Jim Wil­son

Jim Wil­son has been busy late­ly.

Back in May, the AAV pi­o­neer from the Uni­ver­si­ty of Penn­syl­va­nia launched a sec­ond-gen­er­a­tion gene ther­a­py biotech, G2 Bio Com­pa­nies, and just last week un­veiled a non­prof­it aim­ing to serve rare dis­ease pop­u­la­tions where the phar­ma mod­el pro­vides lit­tle eco­nom­ic in­cen­tive. Both ef­forts saw sig­nif­i­cant in­volve­ment from the late Tachi Ya­ma­da, who con­tin­ues to in­spire those work­ing at his lega­cy star­tups.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN